(NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today released its 2025 End‑of‑Year U.S. Sales Tax Rates and Rules Report. Tracking 12,414 U.S. tax ...
Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...
Vertex executives warned that Casgevy, its curative treatment for sickle cell disease, would be slow to reach patients. But ...
Total revenues of $666.8 million for the full year 2024, representing a 16.5% year-over-year increase, indicating strong business growth. Cloud revenues grew by 28.6% year-over-year for the full year ...
Zacks Investment Research on MSN
Wall Street analysts think Vertex (VRTX) is a good investment: Is it?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions ...
Switzerland-based CRISPR Therapeutics (CRSP) and Boston, Massachusetts-based Vertex (VRTX) have been collaborating together since signing an initial agreement in 2015, with Vertex paying CRISPR $75m ...
Vertex Pharmaceuticals released data validating the efficacy and safety of their NaV1.8 inhibitor for chronic neuropathic pain. VX-548 is a potential blockbuster for the treatment of pain and could ...
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs), today announced a global, multi-target license and option agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results